Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | VP Business Development | December 14, 2017 | December 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date December 14, 2017 · Filed December 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,908 |
Ending reported balance
After 2017-12-14 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-12-14 · Exercise / conversion · Acquired 2,646 · Balance 36,554 Row 2 · 2017-12-14 · Exercise / conversion · Acquired 6,021 · Balance 42,575 Row 3 · 2017-12-14 · Exercise / conversion · Acquired 4,062 · Balance 46,637 Row 4 · 2017-12-14 · Sale · Disposed 12,729 · Balance 33,908 F2: $35.3394 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $35.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.91 · Expires 2024-02-27 | Direct | 0 |
Reported balance
After 2017-12-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-14 · Exercise / conversion · Disposed 2,646 · Balance 0 F1: This option is currently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.20 · Expires 2025-02-26 | Direct | 3,010 |
Reported balance
After 2017-12-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-14 · Exercise / conversion · Disposed 6,021 · Balance 3,010 F3: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2026-02-26 | Direct | 8,124 |
Reported balance
After 2017-12-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-12-14 · Exercise / conversion · Disposed 4,062 · Balance 8,124 F3: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is currently exercisable.
F2: $35.3394 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $35.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2017 Filed Dec 18, 2017 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,062 | $0.00 Strike: $26.05 | $0.00 |
DisclosureSEC source: 0001140361-17-046579 · doc1.xml · derivative · entry 7 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,124 Underlying: Common Stock · 4,062 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,021 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001140361-17-046579 · doc1.xml · derivative · entry 6 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 Underlying: Common Stock · 6,021 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,646 | $0.00 Strike: $15.91 | $0.00 |
DisclosureSEC source: 0001140361-17-046579 · doc1.xml · derivative · entry 5 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,646 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 12,729 | $35.34 | $449,835.22 |
DisclosureSEC source: 0001140361-17-046579 · doc1.xml · nonDerivative · entry 4 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,908 F2 · price: $35.3394 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $35.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 4,062 | $26.05 | $105,815.10 |
DisclosureSEC source: 0001140361-17-046579 · doc1.xml · nonDerivative · entry 3 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 6,021 | $26.20 | $157,750.20 |
DisclosureSEC source: 0001140361-17-046579 · doc1.xml · nonDerivative · entry 2 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 2,646 | $15.91 | $42,097.86 |
DisclosureSEC source: 0001140361-17-046579 · doc1.xml · nonDerivative · entry 1 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:41 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001140361-17-012940 · doc1.xml · derivative · entry 6 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:41 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,968 | $0.00 Strike: $15.91 | $0.00 |
DisclosureSEC source: 0001140361-17-012940 · doc1.xml · derivative · entry 5 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,968 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:41 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 10,000 | $6.23 | $62,300.00 |
DisclosureSEC source: 0001140361-17-012940 · doc1.xml · nonDerivative · entry 4 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:41 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 7,248 | $34.63 | $251,009.84 |
DisclosureSEC source: 0001140361-17-012940 · doc1.xml · nonDerivative · entry 3 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,908 F2 · price: $34.6316 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.475 to $34.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:41 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,968 | $34.61 | $171,943.97 |
DisclosureSEC source: 0001140361-17-012940 · doc1.xml · nonDerivative · entry 2 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,156 F1 · price: $34.6103 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.475 to $34.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:41 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 4,968 | $15.91 | $79,040.88 |
DisclosureSEC source: 0001140361-17-012940 · doc1.xml · nonDerivative · entry 1 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 02:00 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,976 | $32.08 | $63,387.31 |
DisclosureSEC source: 0001140361-17-010119 · doc1.xml · nonDerivative · entry 2 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,156 F2 · shares: Payment of tax liability made via forfeiture of 1,976 shares of Common Stock valued at a weighted average of $32.0786 per share on March 1, 2017. Read SEC document |
| February 23, 2017 Filed Mar 2, 2017 02:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 9,012 | $0.00 Strike: $32.32 | $0.00 |
DisclosureSEC source: 0001140361-17-010119 · doc1.xml · derivative · entry 3 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,012 Underlying: Common Stock · 9,012 shares Expires 2027-02-23 F3 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| February 23, 2017 Filed Mar 2, 2017 02:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 4,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010119 · doc1.xml · nonDerivative · entry 1 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,132 F1 · shares: Mr. Benjamin was awarded 4,506 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 23, 2017 Filed Mar 22, 2017 00:23 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 9,012 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0001140361-17-012884 · doc1.xml · derivative · entry 1 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,012 Underlying: Common Stock · 9,012 shares Expires 2027-02-23 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
| February 23, 2017 Filed May 22, 2017 21:15 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 8,289 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0001140361-17-021773 · doc1.xml · derivative · entry 1 Benjamin Howard · CIK 0001393547 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,289 Underlying: Common Stock · 8,289 shares Expires 2027-02-23 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.